Sugi Predict

Sugi Predict / Compounds / SCHEMBL794119

SCHEMBL794119

SCHEMBL794119

O=C1c2cc3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3cc2C(=O)N1CC(O)CO

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 20/20 0.64
▸ CYP3A4 P08684 15/20 0.64
▸ CYP2C19 P33261 9/20 0.64
▸ CYP1A2 P05177 8/20 0.64
▸ CYP2C9 P11712 8/20 0.64
▸ EGFR P00533 2/20 0.57
▸ INSR P06213 2/20 0.57
▸ LCK P06239 2/20 0.57
▸ KDR P35968 2/20 0.57
▸ PTK2 Q05397 2/20 0.57
▸ ERBB2 P04626 1/20 0.57
▸ MET P08581 1/20 0.57
▸ MAP2K1 Q02750 1/20 0.57
▸ PLK4 O00444 1/20 0.57
▸ CHEK1 O14757 1/20 0.57
▸ AURKA O14965 1/20 0.57
▸ PDPK1 O15530 1/20 0.57
▸ DAPK3 O43293 1/20 0.57
▸ DYRK3 O43781 1/20 0.57
▸ JAK2 O60674 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL767739 1.00 IGF1R (0.64) IGF1RCYP3A4CYP2C19CYP1A2CYP2C9
SCHEMBL767740 1.00 IGF1R (0.64) IGF1RCYP3A4CYP2C19CYP1A2CYP2C9
SCHEMBL768041 0.92 IGF1R (0.66) IGF1RCYP3A4CYP2C19CYP1A2CYP2C9
SCHEMBL768042 0.92 IGF1R (0.66) IGF1RCYP3A4CYP2C19CYP1A2CYP2C9
SCHEMBL768955 0.91 IGF1R (0.64) IGF1RCYP3A4CYP2C19CYP1A2CYP2C9
SCHEMBL768954 0.91 IGF1R (0.64) IGF1RCYP3A4CYP2C19CYP1A2CYP2C9
SCHEMBL768577 0.89 IGF1R (0.62) IGF1RCYP3A4CYP2C19CYP1A2CYP2C9
SCHEMBL768578 0.89 IGF1R (0.62) IGF1RCYP3A4CYP2C19CYP1A2CYP2C9
SCHEMBL768264 0.89 IGF1R (0.64) IGF1RCYP3A4CYP2C19CYP1A2CYP2C9
SCHEMBL768263 0.89 IGF1R (0.64) IGF1RCYP3A4CYP2C19CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9290503-B2 Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders CHEMBRIDGE CORPORATION (US) 2016-03-22 — — US disclosed
US-20140228350-A1 TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS CHEMBRIDGE CORPORATION (US) 2014-08-14 — — US disclosed
US-20120071473-A1 TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS CHEMBRIDGE CORPORATION 2012-03-22 — — US disclosed
US-8063225-B2 2-(4-(3-(2,4-Dimethylphenoxy)-2-hydroxypropylamino)-2-oxo-1,2-dihydropyridin-3-yl)-6-(1-methylpiperidin-4-yl)-6,7-dihydroimidazo[4,5-f]isoindol-5(1H)-one; modulating tyrosine kinase; enzyme inhibitors; cancer, diabetes, restenosis, arteriosclerosis, psoriasis, angiogenic diseases, immunologic disorders CHEMBRIDGE CORPORATION (US) 2011-11-22 — — US disclosed
US-8063225-B2 2-(4-(3-(2,4-Dimethylphenoxy)-2-hydroxypropylamino)-2-oxo-1,2-dihydropyridin-3-yl)-6-(1-methylpiperidin-4-yl)-6,7-dihydroimidazo[4,5-f]isoindol-5(1H)-one; modulating tyrosine kinase; enzyme inhibitors; cancer, diabetes, restenosis, arteriosclerosis, psoriasis, angiogenic diseases, immunologic disorders CHEMBRIDGE CORPORATION (US) 2011-11-22 — — US disclosed
EP-2066673-A2 TRICYCLIC COMPOUNDS AND ITS USE AS TYROSINE KINASE MODULATORS ChemBridge Research Laboratories, Inc. (US) 2009-06-10 — — EP disclosed
US-20080171769-A1 Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders CHEMBRIDGE CORPORATION 2008-07-17 — — US disclosed
US-20080171769-A1 Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders CHEMBRIDGE CORPORATION 2008-07-17 — — US disclosed
WO-2008021369-A2 TRICYCLIC COMPOUNDS AND ITS USE AS TYROSINE KINASE MODULATORS CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) 2008-02-21 — — WO disclosed
WO-2008021369-A2 TRICYCLIC COMPOUNDS AND ITS USE AS TYROSINE KINASE MODULATORS CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) 2008-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071473-A1 TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS MALT1, TPMT, TSLP IGF1R 2381/4885CYP3A4 1201/4885CYP2C19 1101/4885
US-20140228350-A1 TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS MALT1, TPMT, TSLP IGF1R 2381/4885CYP3A4 1201/4885CYP2C19 1101/4885
US-20080171769-A1 Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders MALT1, TPMT, TSLP IGF1R 2381/4885CYP3A4 1201/4885CYP2C19 1101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.